Aytu BioPharma, Inc. (AYTU) vs SCYNEXIS, Inc. (SCYX)

Aytu BioPharma, Inc. and SCYNEXIS, Inc. are both Drug Manufacturers Specialty & Generic companies. SCYNEXIS, Inc. is the larger, with a market value of $45.0M against $25.1M — 1.8× the size. SCYNEXIS, Inc. grew revenue faster over the last twelve months: 682.5% against −13.3%. Aytu BioPharma, Inc. has the higher net margin (−24.8% vs −49.7%) and the higher return on invested capital (−20.0% vs −110.7%). Across the 18 metrics below, Aytu BioPharma, Inc. leads on 9 and SCYNEXIS, Inc. on 9.

Valuation

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 0.48 2.52 2.25
P/B 0.78 0.78 1.90
Price to free cash flow 8.53 n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.32 1.15 2.56
Earnings yield (51.16%) (47.61%) (2.99%)
Free cash flow yield 11.72% (25.67%) 0.00%

Profitability

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Gross margin 63.95% 100.00% 53.94%
Operating margin (14.44%) (109.90%) 0.00%
Net margin (24.76%) (49.74%) 0.00%
Free cash flow margin 5.62% (64.67%) 0.00%
Return on equity (52.55%) (18.38%) (0.40%)
Return on assets (12.44%) (15.09%) (3.32%)
Return on invested capital (19.99%) (110.72%) 0.00%

Growth

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (13.27%) 682.47% 10.01%
EPS growth (last fiscal year) 46.44% 61.36% —
Revenue growth, 5-year CAGR (2.59%) 179.40% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Debt to equity 0.48 0.00 0.05
Current ratio 1.13 9.65 2.31
Net debt to EBITDA 2.17 2.54 0.85

Dividend

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AYTU SCYX Drug Manufacturers Specialty & Generic median
Market cap 25.10m 44.98m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack